DRKS00025530已完成4 期
My7steps App Trial Study - M7SA-TS
My7steps GmbH0 个研究点目标入组 253 人开始时间: 2023年6月9日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 253
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. There is legal consent to participate
- •2. The ability to speak and understand German, English or Farsi/Dari
- •3. Between 18 and 65 years old
- •4. Living in Germany
- •5. Diagnosis of any of the following ICD-10 indications: F32.0, F32.1, F33.0, F33.1
排除标准
- •Affected persons who do not meet the inclusion criteria are to be excluded from the study. In addition, people who meet the following criteria are excluded:
- •1. There has been a change in medication within the last 4 weeks
- •2. Participates in other interventional studies
- •3. Is in a dependent or employment relationship with the sponsor or investigator
- •4. Is housed in an institution due to a court or official order
- •5. Suicidal tendencies, diagnosed severe depression, addiction, psychotic symptoms or organic brain disorders (e.g. delirium, dementia) are present
研究者
相似试验
已完成
4 期
My7steps App Pilot StudyF32.0F32.1F33.0F33.1F43.2Mild depressive episodeModerate depressive episodeRecurrent depressive disorder, current episode mildRecurrent depressive disorder, current episode moderateAdjustment disordersDRKS00027925Ipso Healthcare GmbH89
招募中
不适用
TRAILS - Seventh assessment wave TRAILS-CClichamelijke gezondheidsproblemen, zoals pijn of astma(mental) health and social development1003717610024450NL-OMON54717niversitair Medisch Centrum Groningen
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-BETaiho Oncology, Inc.128
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-ESAstex Pharmaceuticals, Inc.168
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-DETaiho Oncology, Inc.168